Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNIK | Q9UKE5 | 5/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 4/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14804131 | 0.90 | FFAR1 (0.42) | TNIKFFAR1FFAR4ERBB2EGFR | |
| SCHEMBL14800428 | 0.89 | TNIK (0.40) | TNIKFFAR1FFAR4ERBB2EGFR | |
| SCHEMBL14801382 | 0.86 | TNIK (0.42) | TNIKGRM5FFAR1FFAR4ERBB2 | |
| SCHEMBL14804136 | 0.76 | FFAR1 (0.44) | FFAR1FFAR4ERBB2MET | |
| SCHEMBL14800394 | 0.74 | CDK4 (0.37) | GRM5 | |
| SCHEMBL14800393 | 0.74 | CDK4 (0.37) | GRM5 | |
| SCHEMBL14800991 | 0.74 | GRM5 (0.39) | GRM5 | |
| SCHEMBL14800725 | 0.74 | MAPT (0.45) | TNIKERBB2EGFRCYP19A1CYP11B1 | |
| SCHEMBL14800906 | 0.73 | ENPP2 (0.45) | GRM5 | |
| SCHEMBL14800038 | 0.69 | MIF (0.44) | TNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2760843-B1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2016-03-02 | — | — | EP | disclosed |
| US-8841301-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-23 | — | — | US | disclosed |
| WO-2013048949-A2 | SELECTIVE NR2B ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| US-20130079338-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079338-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | TNIK 2922/4885GRM5 20/4885FFAR1 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.